Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T21:12:23.872Z.
Calculation as of: 2026-10-06T21:12:23.872Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2eba736d2827de544c9f141b3fafa3dea8ffa5f0a614b8c2b2ac1915a5af89f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$241.94M
EV/FCF Ratio
N/A
TTM Avg
894.08x
3Y Avg
541.45x
5Y Avg
277.55x
Market Cap
$235.97M
EV/FCF Ratio
N/A
TTM Avg
3.75x
3Y Avg
11.33x
5Y Avg
12.44x
Market Cap
$235.66M
EV/FCF Ratio
3.34x
TTM Avg
5.14x
3Y Avg
5.14x
5Y Avg
5.14x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $239.02M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.01M | 25.58x | 23.33x | 20.20x | 22.09x |
| Invivyd, Inc. (IVVD)vs › | $237.57M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | N/A | 9.08x | 9.08x | 9.08x |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 894.08x | 541.45x | 277.55x |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | N/A | 3.75x | 11.33x | 12.44x |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 3.34x | 5.14x | 5.14x | 5.14x |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 20.55x | 10.38x | 8.72x | 10.56x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
